Maravai LifeSciences Holdings Inc. Class A Common Stock vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Vanguard Total Stock Market Index Fund ETF trades at $375.71 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 2364.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Vanguard Total Stock Market Index Fund ETF for 132 Days on average.
| MRVI | VTI | |
|---|---|---|
Market Cap | $972.90M | $2.30T |
Volume | 4,325,710 | 2,460,185 |
Sector | Health | — |
52-Week High | $9.00 | $384.30 |
52-Week Low | $2.83 | $311.68 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $1.08B | — |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
VTI trades at $381.32, down slightly by 0.07% today, with a bullish technical signal driven by strong moving average alignment. The ETF offers broad U.S. equity exposure, though key financial ratios are not provided in the data. Recent news highlights its appeal for long-term investors seeking diversification and low-cost market access.
The outlook remains positive given strong technical momentum and media optimism, but risks include market concentration in top holdings and broader economic volatility. Investors benefit from VTI's extensive diversification, yet should monitor allocation weights and macroeconomic trends for potential impacts on returns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →